I get this question every single day, and honestly, I love it. It tells me you’re ready. You’ve probably seen the posts online, people sharing their before-and-after photos, down 30 pounds, 50 pounds, sometimes more. And you’re wondering: could that be me?
The honest answer? It could be. But I want to give you something better than social media highlights. I want to give you real data, real timelines, and real expectations so you can walk into this feeling prepared and empowered, not just hopeful.
In one large clinical trial, people taking tirzepatide lost an average of 15 to 20 percent of their starting body weight over 72 weeks. For someone starting at 200 to 250 pounds, that works out to roughly 30 to 50 pounds. Those are real, meaningful numbers.
At InjectCo, we run a physician-guided compounded tirzepatide program across our 9 Texas locations, and what we see in our patients lines up closely with the clinical data. What I’ve noticed time and again is that the patients who hit those numbers aren’t just taking the medication. They have the structure around it. And that’s exactly what we’re here to help you build.
Before we get into the week-by-week details, here’s a snapshot of what the data shows across different starting weights. Keep in mind these are ranges based on the SURMOUNT-1 trial and real-world compounded tirzepatide outcomes. Your results will depend on your starting weight, dosage, consistency, and lifestyle.
| Starting Weight | 3 Months | 6 Months | 12 Months |
| 180 lbs | 9-18 lbs | 18-32 lbs | 27-40 lbs |
| 200 lbs | 10-20 lbs | 20-36 lbs | 30-44 lbs |
| 225 lbs | 11-23 lbs | 23-40 lbs | 34-50 lbs |
| 250 lbs | 13-25 lbs | 25-45 lbs | 38-55 lbs |
| 275 lbs | 14-28 lbs | 28-50 lbs | 41-61 lbs |
These ranges are based on the SURMOUNT-1 trial data and real-world compounded tirzepatide outcomes. Individual results depend on starting weight, dosage, consistency, and lifestyle.
One of the most common things I hear at consultations is, “I just want to know what to expect at week 4.” Month 12 feels far away. Week 4 feels real. So let’s talk about that.
Here’s what the clinical data and our patient experience show, stage by stage:
| Stage | Timeframe | What to Expect | Notes |
| Adjustment | Weeks 1-2 | Appetite begins to decrease. Little to no scale movement yet. | Body adapting to the 2.5 mg starting dose. |
| Early Loss | Weeks 3-4 | First noticeable weight loss. Most patients lose 2-5 lbs. | Food noise quiets significantly for most. |
| Acceleration | Weeks 5-8 | Weight loss becomes consistent. 1-2 lbs per week is common. | Dose typically increases at the 4-week mark. |
| Active Phase | Months 3-6 | 5-10% total body weight loss. Energy and mobility improve. | Highest rate of loss for most patients. |
| Sustained Loss | Months 6-12 | 10-20% total body weight loss. Plateaus are normal here. | Dose adjustments may occur. Lifestyle habits matter more. |
| Maintenance | Month 12+ | 15-22% total body weight loss on higher doses. | Long-term use supports sustained results per clinical trials. |
The first month can feel slow, and I always want patients to know: the medication is working even when the scale isn’t moving yet. The appetite changes you feel in weeks 1 and 2 are the foundation for everything that comes after. Trust the process.
The clinical average is 1 to 2 pounds per week, but this isn’t a straight line. Most patients lose more in the first three months as the body responds to reduced caloric intake, and then the rate slows and steadies out.
In our Texas clinics, patients on the full titration schedule (starting at 2.5 mg and working up to 10 to 15 mg over several months) tend to see the best weekly averages when they stay consistent with their protein intake and injection schedule.
Here are some realistic benchmarks based on trial data:
Slower weeks are completely normal and don’t mean the medication isn’t working. Plateaus around months 3 and 4 are common, and they’re usually temporary. I promise.
Most patients lose 4 to 8 pounds in their first month. Some lose more, especially if they start with a higher body weight or pair the medication with meaningful dietary changes.
The first month uses the 2.5 mg dose, which is intentionally conservative. It’s designed to minimize side effects and let your body adjust, not to maximize weight loss right out of the gate. Please don’t judge the medication by month one results alone. The meaningful data really starts at month three.
I think about one of my patients, a woman in her early 50s from the Plano area. She lost 6 pounds in her first month and called me frustrated. By month four, she had lost 28 pounds. What I told her is what I tell everyone: the first month is the foundation, not the finish line.
Three months is the first real milestone worth celebrating. By this point, most patients have completed their initial dose titration and are approaching or sitting at the 7.5 to 10 mg range.
Clinical trial data from the SURMOUNT-1 study shows an average of 7 to 10% body weight loss at the three-month mark. For someone starting at 220 pounds, that’s roughly 15 to 22 pounds.
What tends to drive results in this window? Consistent weekly injections, hitting 80 to 100 grams of protein daily, and some form of regular movement. Patients who skip doses or cut calories too aggressively tend to see slower progress and more muscle loss. We don’t want either of those things for you.
I want to be really honest with you here. Two patients can be on the same dose, in the same program, and see different results. That’s not a flaw in the medication. It reflects the complexity of your metabolism and body composition. Here’s what actually matters:
Patients with more weight to lose typically see larger absolute losses, though the percentage lost usually stays in that same 15 to 22% range.
Patients who complete the full titration schedule and consistently reach 10 to 15 mg tend to see the best results. Staying at a lower dose because of side effects is completely valid, but it does lower your ceiling. We work with you on this.
Thyroid health, insulin resistance, cortisol levels, and for women, perimenopause and menopause can all slow the response. That’s why we recommend baseline labs before you start. If something is working against you, we want to catch it early.
The clinical guidance for patients on GLP-1 and GIP receptor agonists is to target 60 to 75 grams of protein per day, and up to 1.5 grams per kilogram of body weight on an individualized basis. This is not optional. Patients who don’t prioritize protein see more muscle loss and slower long-term results. I know it feels like a lot at first, but it makes a real difference.
The medication does the heavy lifting on appetite, but it works best when paired with real behavioral changes. Patients who still rely heavily on processed foods or consistently skip protein tend to hit plateaus sooner. You don’t have to be perfect. But consistency matters.
This is one of the most common questions we get, and I want you to know: it almost always has an answer. If you’ve been on tirzepatide and the scale hasn’t moved in two to four weeks, here’s what to check first:
If the plateau stretches beyond four to six weeks, please reach out to your provider. A dose adjustment may be appropriate, or there may be an underlying metabolic issue worth looking into. You don’t have to figure this out alone.
The SURMOUNT-5 trial, published in 2025 in the New England Journal of Medicine, compared tirzepatide directly against a GLP-1 comparator over 72 weeks. Participants on tirzepatide lost an average of 50 pounds, compared to 33 pounds on the comparator. That’s nearly 50 percent more weight loss.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it targets two hormonal pathways instead of one. That dual mechanism appears to produce stronger appetite suppression and greater fat mass reduction in clinical trials.
At InjectCo, we offer both compounded tirzepatide and compounded semaglutide programs. The right fit depends on your metabolic history, how you’ve responded to prior treatments, and your goals. If you’ve already tried a GLP-1 program and hit a wall, tirzepatide is often the stronger next step.
I want to answer this one directly, because I get it a lot and I think there’s a lot of fear around it.
Yes, some lean mass reduction is normal with any significant weight loss, including medication-assisted programs. The SURMOUNT-3 MRI substudy showed that about 25% of total weight lost on tirzepatide came from lean mass, with 75% from fat mass. That ratio is actually consistent with what we see in diet-only or exercise-only approaches.
True muscle wasting is a different story, and it’s almost always caused by inadequate protein and severe caloric restriction, not by the medication itself. Here’s what actually protects your muscle:
Our tirzepatide programs at InjectCo include nutrition guidance built specifically around these targets. It’s not a separate service. It’s part of what you get every month.
These are paraphrased accounts from public platforms. Results vary based on individual factors.
Diet and exercise worked well into this patient’s 30s, then stopped working despite consistent effort. After starting tirzepatide, the trajectory changed. Down from 210 to 140 over about 14 months, with maintenance ongoing.
After years of trying multiple approaches with no lasting result, this patient saw appetite control unlike anything they had experienced. Sugar cravings dropped within the first two weeks. Down 27 pounds by week 8, with joint pain reduced enough to exercise again.
This patient had already lost about 15% of their starting weight on a different GLP-1 program. After switching to tirzepatide at the starting dose, they noticed faster loss and stronger appetite suppression even at the lowest dose.
A 64-year-old man who had struggled with weight despite calorie tracking and exercise. Weekly injections at the starting dose. Down 40 pounds over about 2 months. No significant side effects reported beyond initial mild nausea.
The medication handles the appetite side. These habits are what determine how much of that advantage you actually convert into lasting results:
Let’s talk about the money side of things, because I know it matters.
The average monthly cost for brand-name tirzepatide without insurance runs $1,000 to $1,300 per month. Insurance coverage exists for some patients but is inconsistent depending on the indication and your specific plan.
Compounded tirzepatide is a more accessible option. At InjectCo, our physician-guided compounded tirzepatide program starts at $425 per month, and that includes the medication, physician oversight, and monthly progress reviews. Here’s how that breaks down:
| Brand-Name | Compounded (InjectCo) | |
| Monthly Cost | $1,000-$1,300 | From $425/month |
| Physician Oversight | Varies by provider | Included |
| Progress Reviews | Varies | Monthly |
| Insurance Coverage | Sometimes | Out-of-pocket |
| Availability | Pharmacy-dependent | 9 Texas locations |
Flexible payment options are available through CareCredit and Cherry. Both can be applied at the time of your consultation.
Tirzepatide is typically a strong option if you have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition such as high blood pressure, type 2 diabetes, or sleep apnea.
It may not be appropriate if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or if you are pregnant or planning to become pregnant. A full medical evaluation will identify any contraindications before you start.
The best way to know if it’s the right step for you is a real conversation with a provider who can look at your full health history. At InjectCo, that conversation starts with a free 15-minute virtual consultation. No commitment required. Just a chance to get your questions answered.
Book your free virtual consultation with InjectCo
The clinical average is 15 to 22 percent of starting body weight over the course of treatment. For someone at 200 pounds, that is 30 to 44 pounds. Results at 12 months on the highest doses (15 mg) have reached 20.9 percent in the SURMOUNT-1 trial.
Most patients lose 4 to 8 pounds in the first month. The starting dose of 2.5 mg is intentionally conservative to minimize side effects, so month one results are lower than later months. Do not judge your progress on month one numbers.
Most patients lose 7 to 10 percent of their starting body weight by month 3. For someone at 200 pounds, that is approximately 14 to 20 pounds. By this point, most patients have completed initial dose titration and are seeing consistent weekly loss.
The average is 1 to 2 pounds per week once the active loss phase begins, typically around weeks 3 to 4. Some weeks will be faster, some will plateau. The weekly average across a 72-week trial period works out to approximately 0.5 to 0.7 pounds per week when spread across the full titration and maintenance period.
The most common reasons are calorie compensation (eating calorie-dense foods despite reduced appetite), insufficient protein intake, inconsistent dosing, or a natural plateau at months 3 to 4. If you have not lost weight in 4 to 6 weeks, contact your provider to review your dose and nutrition.
Some lean mass reduction is a normal part of any significant weight loss, around 25 percent of total weight lost in clinical trials. True muscle wasting is rare and almost always tied to inadequate protein and severe caloric restriction. Eating 1.0 to 1.5 grams of protein per kilogram of body weight daily and including resistance exercise significantly reduces lean mass loss.
Most patients stay on tirzepatide as long as it continues to support their weight management goals, which can mean long-term use. Clinical trial data at 88 weeks shows that patients who stopped the medication regained a significant portion of their weight, which underscores the value of a continued maintenance plan.
Our physician-guided compounded tirzepatide program starts at $425 per month, which includes the medication, physician oversight, and monthly progress reviews. Flexible payment options through CareCredit and Cherry are available.
Clinical trial data from the SURMOUNT-5 trial shows tirzepatide produced approximately 47 percent more weight loss than a semaglutide comparator over 72 weeks (average of 50 pounds versus 33 pounds). Tirzepatide targets two hormonal pathways (GIP and GLP-1) compared to one, which appears to account for the difference.
InjectCo offers a physician-guided compounded tirzepatide weight loss program across 9 Texas locations including Fort Worth, Plano, Dallas, Colleyville, Argyle, Cleburne, Waxahachie, The Woodlands, and Austin. Start with a free 15-minute virtual consultation at injectco.com.
Insurance coverage varies. Plans may cover tirzepatide for patients with type 2 diabetes or obesity-related conditions. For weight loss without a qualifying diagnosis, coverage is inconsistent. InjectCo’s compounded program is out-of-pocket, with financing available through CareCredit and Cherry.
Written By: Kiara DeWitt, BSN, RN, CPN
Kiara DeWitt, BSN, RN, CPN is the founder of InjectCo MedSpa and a former lead clinical educator in the neurosurgery and neurology unit at Cook Children’s Pediatric Hospital. She earned her nursing degree from Texas Christian University and has performed thousands of aesthetic treatments across InjectCo’s 9 Texas locations. She founded the Texas Academy of Medical Aesthetics to raise the standard of nurse-led aesthetic care statewide.
days day
hours hour
minutes minute
seconds second
